Seeking Alpha

Johnson & Johnson (JNJ) applies for U.S. and European regulatory approval of a new...

Johnson & Johnson (JNJ) applies for U.S. and European regulatory approval of a new manufacturing process that would provide a short-term fix to the supply shortage of its Doxil cancer drug. Under JNJ's plan, existing contract manufacturer Ben Venue Labs would produce Doxil while a second supplier would handle other tasks such as ensuring the drug is sterile.
Comments (1)
  • followthemoney
    , contributor
    Comments (16) | Send Message
     
    waiting for a good price to buy more.
    8 Oct 2012, 06:00 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|